表紙
市場調査レポート

頭頚部扁平上皮癌:パイプライン製品の分析

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251612
出版日 ページ情報 英文 713 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
頭頚部扁平上皮癌:パイプライン製品の分析 Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 713 Pages
概要

頭頚部(鼻腔内、副鼻腔内、唇、口、唾液腺、喉、喉頭)から発生する癌であり、喉の持続性の痛み、嚥下障害あるいは痛み、持続性の枯声、声の変化、耳の痛み、 口内あるいは喉からの出血などの症状があります。管理方法には、化学療法や放射線治療があります。

当レポートでは、世界における頭頚部扁平上皮癌治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

  • 調査範囲

頭頚部扁平上皮癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

頭頚部扁平上皮癌:企業で開発中の治療薬

頭頚部扁平上皮癌:大学/機関で研究中の治療薬

頭頚部扁平上皮癌:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

頭頚部扁平上皮癌:企業で開発中の製品

頭頚部扁平上皮癌:大学/機関で研究中の製品

頭頚部扁平上皮癌の治療薬開発に従事している企業

  • AB Science SA
  • AbbVie Inc.
  • Acceleron Pharma, Inc.
  • Advaxis, Inc.
  • Altor BioScience Corporation
  • Amgen Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Bionovis SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • CEL-SCI Corporation
  • Cellceutix Corporation
  • Celldex Therapeutics, Inc.
  • Celltrion, Inc.
  • Centrose LLC
  • Critical Outcome Technologies Inc.
  • 第一三共
  • Debiopharm International SA
  • エーザイ
  • Eli Lilly and Company
  • Etubics Corporation
  • F. Hoffmann-La Roche Ltd.
  • G&E Herbal Biotechnology Co., Ltd.
  • Genexine, Inc.
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Gliknik, Inc.
  • Glycotope GmbH
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Horizon Pharma Plc
  • Immunomedics, Inc.
  • Immunovative Therapies, Ltd.
  • Incyte Corporation
  • Innate Pharma S.A.
  • Inovio Pharmaceuticals, Inc.
  • IRX Therapeutics, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Laboratoires Pierre Fabre SA
  • Loxo Oncology, Inc.
  • Mabion SA
  • MacroGenics, Inc.
  • Marsala Biotech Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • Merrimack Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Mirati Therapeutics Inc.
  • Molecular Partners AG
  • Molplex Ltd.
  • Novartis AG
  • Oncobiologics, Inc.
  • Oncolytics Biotech Inc.
  • Onconova Therapeutics, Inc.
  • OncoSec Medical Incorporated
  • Ono Pharmaceutical Co., Ltd.
  • OXiGENE, Inc.
  • Panacea Biotec Limited
  • PCI Biotech Holding ASA
  • Pfizer Inc.
  • Sanofi
  • Shanghai Henlius Biotech Co., Ltd.
  • Shenzen SiBiono GeneTech Co., Ltd.
  • 塩野義製薬
  • Sillajen Biotherapeutics
  • Symphogen A/S
  • Synta Pharmaceuticals Corp.
  • タカラバイオ Inc.
  • Threshold Pharmaceuticals, Inc.
  • UbiVac, LLC
  • VasGene Therapeutics, Inc.
  • VentiRx Pharmaceuticals, Inc.
  • Virttu Biologics Limited
  • Viventia Bio Inc.
  • Vyriad

頭頚部扁平上皮癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

頭頚部扁平上皮癌:最近のパイプライン動向

頭頚部扁平上皮癌:休止中のプロジェクト

頭頚部扁平上皮癌:開発が中止された製品

頭頚部扁平上皮癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7988IDB

Summary

Global Markets Direct's, 'Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016', provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
  • The report reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Head And Neck Cancer Squamous Cell Carcinoma therapeutics and enlists all their major and minor projects
  • The report assesses Head And Neck Cancer Squamous Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Head And Neck Cancer Squamous Cell Carcinoma Overview
  • Therapeutics Development
    • Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview
    • Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis
  • Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies
  • Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies
  • Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes
  • Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development
    • AB Science SA
    • AbbVie Inc.
    • Acceleron Pharma, Inc.
    • Advaxis, Inc.
    • Altor BioScience Corporation
    • Amgen Inc.
    • AstraZeneca Plc
    • AVEO Pharmaceuticals, Inc.
    • Bayer AG
    • Bionovis SA
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • CEL-SCI Corporation
    • Cellceutix Corporation
    • Celldex Therapeutics, Inc.
    • Celltrion, Inc.
    • Centrose LLC
    • Critical Outcome Technologies Inc.
    • Daiichi Sankyo Company, Limited
    • Debiopharm International SA
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Etubics Corporation
    • F. Hoffmann-La Roche Ltd.
    • G&E Herbal Biotechnology Co., Ltd.
    • Genexine, Inc.
    • Genmab A/S
    • GlaxoSmithKline Plc
    • Gliknik, Inc.
    • Glycotope GmbH
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Horizon Pharma Plc
    • Immunomedics, Inc.
    • Immunovative Therapies, Ltd.
    • Incyte Corporation
    • Innate Pharma S.A.
    • Inovio Pharmaceuticals, Inc.
    • IRX Therapeutics, Inc.
    • Kolltan Pharmaceuticals, Inc.
    • Laboratoires Pierre Fabre SA
    • Loxo Oncology, Inc.
    • Mabion SA
    • MacroGenics, Inc.
    • Marsala Biotech Inc.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Merck KGaA
    • Merrimack Pharmaceuticals, Inc.
    • Millennium Pharmaceuticals, Inc.
    • Mirati Therapeutics Inc.
    • Molecular Partners AG
    • Molplex Ltd.
    • Novartis AG
    • Oncobiologics, Inc.
    • Oncolytics Biotech Inc.
    • Onconova Therapeutics, Inc.
    • OncoSec Medical Incorporated
    • Ono Pharmaceutical Co., Ltd.
    • OXiGENE, Inc.
    • Panacea Biotec Limited
    • PCI Biotech Holding ASA
    • Pfizer Inc.
    • Sanofi
    • Shanghai Henlius Biotech Co., Ltd.
    • Shenzen SiBiono GeneTech Co., Ltd.
    • Shionogi & Co., Ltd.
    • Sillajen Biotherapeutics
    • Symphogen A/S
    • Synta Pharmaceuticals Corp.
    • Takara Bio Inc.
    • Threshold Pharmaceuticals, Inc.
    • UbiVac, LLC
    • VasGene Therapeutics, Inc.
    • VentiRx Pharmaceuticals, Inc.
    • Virttu Biologics Limited
    • Viventia Bio Inc.
    • Vyriad
  • Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABBV-221 - Drug Profile
    • AdIL-24 - Drug Profile
    • afatinib dimaleate - Drug Profile
    • alisertib - Drug Profile
    • AlloVax - Drug Profile
    • alpelisib - Drug Profile
    • ALT-803 - Drug Profile
    • AMG-319 - Drug Profile
    • Antibodies to Inhibit FRMD4A for Oncology - Drug Profile
    • Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
    • AV-203 - Drug Profile
    • avelumab - Drug Profile
    • axalimogene filolisbac - Drug Profile
    • AZD-5069 - Drug Profile
    • AZD-6738 - Drug Profile
    • AZD-9150 - Drug Profile
    • bleomycin sulfate - Drug Profile
    • BMS-986016 - Drug Profile
    • BNV-003 - Drug Profile
    • buparlisib hydrochloride - Drug Profile
    • cabazitaxel - Drug Profile
    • capmatinib - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
    • cetuximab - Drug Profile
    • cetuximab biobetter - Drug Profile
    • cetuximab biosimilar - Drug Profile
    • cetuximab biosimilar - Drug Profile
    • cetuximab biosimilar - Drug Profile
    • cetuximab biosimilar - Drug Profile
    • cetuximab biosimilar - Drug Profile
    • cetuximab biosimilar - Drug Profile
    • copanlisib hydrochloride - Drug Profile
    • COTI-2 - Drug Profile
    • dalantercept - Drug Profile
    • Debio-1143 - Drug Profile
    • depatuxizumab - Drug Profile
    • DNA IL-12 - Drug Profile
    • DPV-001 - Drug Profile
    • DTP-348 - Drug Profile
    • durvalumab - Drug Profile
    • durvalumab + tremelimumab - Drug Profile
    • E-10A - Drug Profile
    • E-7046 - Drug Profile
    • EBC-46 - Drug Profile
    • EDC-2 - Drug Profile
    • elgemtumab - Drug Profile
    • enoblituzumab - Drug Profile
    • epacadostat - Drug Profile
    • ETBX-041 - Drug Profile
    • everolimus - Drug Profile
    • ficlatuzumab - Drug Profile
    • futuximab - Drug Profile
    • ganetespib - Drug Profile
    • gedatolisib - Drug Profile
    • Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile
    • Gene Therapy to Activate p53 for Oncology - Drug Profile
    • GL-0817 - Drug Profile
    • golvatinib tartrate - Drug Profile
    • GS-10 - Drug Profile
    • GSK-2636771 - Drug Profile
    • GSK-2849330 - Drug Profile
    • GSK-3174998 - Drug Profile
    • GX-051 - Drug Profile
    • HF-10 - Drug Profile
    • HSV-1716 - Drug Profile
    • IC-1001 - Drug Profile
    • INCB-50465 - Drug Profile
    • INO-3106 - Drug Profile
    • INO-3112 - Drug Profile
    • interferon gamma-1b - Drug Profile
    • IRX-2 - Drug Profile
    • JX-929 - Drug Profile
    • KGP-94 - Drug Profile
    • KM-3174 - Drug Profile
    • KTN-3379 - Drug Profile
    • lenvatinib mesylate - Drug Profile
    • Leukocyte Interleukin - Drug Profile
    • LGK-974 - Drug Profile
    • lirilumab - Drug Profile
    • LN-145 - Drug Profile
    • LOXO-101 - Drug Profile
    • lumretuzumab - Drug Profile
    • masitinib - Drug Profile
    • MEDI-0562 - Drug Profile
    • merestinib - Drug Profile
    • MGCD-265 - Drug Profile
    • MGD-009 - Drug Profile
    • monalizumab - Drug Profile
    • Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
    • Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
    • motolimod - Drug Profile
    • MP-0250 - Drug Profile
    • nilotinib - Drug Profile
    • nimotuzumab - Drug Profile
    • nivolumab - Drug Profile
    • NP-001 - Drug Profile
    • olaparib - Drug Profile
    • Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
    • Oncolytic Virus to Target CD46 for Recurrent Squamous Cell Carcinoma Head and Neck Cancer - Drug Profile
    • palbociclib - Drug Profile
    • panitumumab - Drug Profile
    • patritumab - Drug Profile
    • pelareorep - Drug Profile
    • pembrolizumab - Drug Profile
    • PF-04518600 - Drug Profile
    • PF-06801591 - Drug Profile
    • poziotinib - Drug Profile
    • prexasertib - Drug Profile
    • Recombinant Peptide to Target EGFR for Oncology - Drug Profile
    • Recombinant Protein for Oncology - Drug Profile
    • rigosertib sodium - Drug Profile
    • S-488210 - Drug Profile
    • sacituzumab - Drug Profile
    • SB-01 - Drug Profile
    • seribantumab - Drug Profile
    • SF-1126 - Drug Profile
    • Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
    • Small Molecules to Inhibit 16S rRNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer - Drug Profile
    • Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
    • Small Molecules to Inhibit IL-6 for Head and Neck Squamous Cell Carcinoma - Drug Profile
    • solarise - Drug Profile
    • Synthetic Peptide for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile
    • tarloxotinib bromide - Drug Profile
    • tisotumab vedotin - Drug Profile
    • trametinib dimethyl sulfoxide + uprosertib - Drug Profile
    • UBS-109 - Drug Profile
    • urelumab - Drug Profile
    • utomilumab - Drug Profile
    • varlilumab - Drug Profile
    • Vas-01 - Drug Profile
    • VB-4847 - Drug Profile
    • vinflunine ditartrate - Drug Profile
  • Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects
  • Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products
  • Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2016
  • Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AB Science SA, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Altor BioScience Corporation, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bayer AG, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bionovis SA, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose LLC, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Debiopharm International SA , H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Etubics Corporation, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genmab A/S, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Horizon Pharma Plc, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma S.A., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by IRX Therapeutics, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Loxo Oncology, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Marsala Biotech Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molecular Partners AG, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncobiologics, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Incorporated, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OXiGENE, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech Holding ASA, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sanofi, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by UbiVac, LLC, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Bio Inc., H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Vyriad, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..1), H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..2), H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..3), H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H1 2016
  • Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2016
  • Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top